Raymond James Financial
TENX icon

Raymond James Financial’s Tenax Therapeutics TENX Stock Holding History

Raymond James Financial’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
+117,482
New +$1.5M ﹤0.01% 3606
2025
Q3 		– Sell
-1,503
Closed -$8.66K – 6599
2025
Q2 		$8.66K Buy
+1,503
New +$8.69K ﹤0.01% 5977

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Raymond James Financial's TENX Position: Q2 2026 in Review

Raymond James Financial opened a new position in Tenax Therapeutics (TENX) in Q2 2026: 117,482 shares worth $1.71M. The stake represents ﹤0.01% of the portfolio and ranks #3606 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in TENX as recently as Q2 2025.

Raymond James Financial first reported a position in TENX in Q2 2025 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Raymond James Financial held 117,482 shares of Tenax Therapeutics worth $1.71M as of Q2 2026.
  • Tenax Therapeutics was a new Raymond James Financial position in Q2 2026.
  • Tenax Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3606 holding.
  • Raymond James Financial first reported a position in Tenax Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.